Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with on-label multiple myeloma use, including prior therapy and relapsed/refractory context, but several statements are overly generalized and omit the label’s specific requirements (lenalidomide and proteasome inhibitor exposure; progression on or within 60 days of last therapy) and regimen structure details (must be in combination with dexamethasone).
Category Scores
Accurate Statements
Pomalyst (pomalidomide) has label indications for multiple myeloma in particular settings.
Supported by label section 1.1 (Multiple Myeloma): indicated for adult patients with MM meeting specific prior-therapy and progression criteria.
Pomalyst is indicated for multiple myeloma in patients who have had prior therapy.
Supported by label section 1.1 requiring at least two prior therapies (including lenalidomide and a proteasome inhibitor) and disease progression on or within 60 days of completion of last therapy.
Pomalyst is used in relapsed or refractory multiple myeloma.
Supported by label section 1.1 using the label’s progression criterion on or within 60 days of completion of last therapy (relapsed/refractory concept reflected by progression after prior therapies).
Pomalyst is used in relapsed or refractory multiple myeloma typically after patients have already received other treatments.
Supported generally by label section 1.1 specifying at least two prior therapies prior to treatment and progression after the last therapy.
Pomalyst is commonly referenced for use after prior line(s) of therapy when the disease has returned or does not respond to treatment.
Supported generally by label section 1.1 requiring disease progression after prior therapies; however, the claim is broad and not restricted to the label’s exact prior-therapy criteria.
In multiple myeloma, Pomalyst is most often discussed as part of a combination regimen depending on the specific labeled regimen.
Supported by label section 1.1 stating POMALYST is indicated in combination with dexamethasone.
Pomalyst is discussed as being used with dexamethasone in multiple myeloma regimens.
Supported by label section 1.1: POMALYST, in combination with dexamethasone.
Unsupported Statements
Pomalyst (pomalidomide) is an immunomodulatory drug used for specific blood cancers.
The provided label excerpts do not contain a statement describing pomalidomide as an immunomodulatory drug or the phrase 'specific blood cancers' as such.
Pomalyst has label indications for multiple myeloma in particular settings.
While multiple myeloma indication is supported, the claim is too nonspecific to verify the 'particular settings' details beyond the cited progression/prior-therapy criteria. (This is treated as partially supported overall; no direct contradiction.)
Pomalyst is used in relapsed or refractory multiple myeloma typically after patients have already received other treatments.
Supported in concept by prior-therapy requirements, but 'typically' is not a label-supported frequency/timing descriptor.
Pomalyst is most often discussed as part of a combination regimen depending on the specific labeled regimen.
The label supports combination with dexamethasone, but 'most often discussed' is not label-supported.
Contradictions
Important Omissions
Specific labeled eligibility details: adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, with disease progression on or within 60 days of completion of the last therapy (and combination with dexamethasone).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims relate primarily to indication context and combination use; no pregnancy/contraindication, dosing, monitoring, or interaction claims were made in the AI response list that would directly conflict with provided contraindication warnings.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements are generalized (e.g., 'immunomodulatory,' 'typically after,' 'commonly referenced') and omit key label-specific eligibility criteria (prior therapy types/count and timing/progression window).
Suggested Improvement
Rephrase to mirror label wording: POMALYST in combination with dexamethasone is indicated for adult multiple myeloma patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.